Prospects Fund

Prospects Oncology Fund

prospect-oncology-fund-imgFACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Ontario First Investment Strategy and have the potential to act as deal flow for the Compass Rose Fund. Prospects funding ranges between $50,000 and $200,000.

Funding is governed by a research contract which grants certain rights to FACIT.   FACIT receives no financial consideration on Prospects awards of $50,000 or less (***new limit as of September 2019***).  On all other awards, FACIT receives an option to make an investment at the Compass Rose level and act as the agent for commercialization, if mutually agreed.  If the option is exercised, funding received from the Prospects Fund will be credited towards FACIT's Compass Rose investment.

How to apply:

The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:

  • March 31
  • September 30

The pre-submission form can be downloaded here.

Late applications will not be considered.

Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.

Select Prospects Funded Projects

Prospects Fund (Other)

A novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performance

Nanology Labs has developed a low toxicity MRI contrast agent which circumvents limitations of other agents currently available.

A novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performanceA novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performance


Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation

Further development of promising potent compounds in triple-negative breast cancer models.

Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell ProliferationInhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation


Universal CAR-T Therapy

Development of a universally compatible (allogeneic) source for the next generation of CAR-T therapies based on hematopoietic stem cells harvested from healthy donors.

Universal CAR-T TherapyUniversal CAR-T Therapy


ADC Linker Platform

Further development of novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC).

ADC Linker PlatformADC Linker Platform


View All Prospects Funded Projects